BLOG
Les messages fallacieux des radios US et des antis loi COVID
Certains podcasts et radios américaines produisent des émissions scientifiquement trompeuses sur le Covid. Les opposants de la loi Covid aussi.
Socrates n’est pas un coronavirus
Les opposants aux mesures sanitaires, aux campagnes de vaccination et au certificat Covid commettent régulièrement des erreurs de logique à cause d’un emploi inadéquat des syllogismes.
Le port du masque est efficace pour réduire la transmission, le vaccin aussi
L’obligation du port du masque est régulièrement attaquée. Qu’en est-il des preuves scientifiques ?
L’initiative dite 99% est un poison contre l’innovation
Le 26 septembre nous voterons sur l’initiative lancée par la Jeunesse socialiste, visant à taxer à 150% les revenus du capital.
Comme vaccin, prendrons-nous une copie ou un original ?
Lever les brevets sur les vaccins pose la question des détenteurs de l’autorisation de mise sur le marché de produits biosimilaires
NEWS
NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance
NETRIS Pharma initiates the Phase 2 ImmunoNET trial to test NP137, as add- on therapy for immunotherapy resistance.
€31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners
Mablink has raised a €31 million Series A funding round led by Sofinnova Partners and Mérieux Equity Partners, with participation from the existing investors.
NETRIS Pharma, Orano and Centre Léon Bérard Announce Scientific Collaboration to Develop Novel Antibody Radio-Conjugate Therapies
NETRIS Pharma announced today that it has entered into a scientific collaboration agreement with Orano and CLB to develop novel Antibody Radio-Conjugates for the treatment of cancer.
Mablink Bioscience announces appointment of its Head of Preclinical Research and Development
Mablink Bioscience appoints Dr. Lenka Kyrych Sadilkova as its Head of Preclinical Research and Development to support the development of its pipeline of ADC candidates
Mablink Bioscience announces appointment of its Chief Development Officer
Mablink Bioscience appoints its Chief Development Officer to support the regulatory development of its lead candidate MBK-103, an ADC using its proprietary PSARlink technology
Dr. Thierry Fumeaux, as new CEO at Acthera
Acthera has appointed Thierry Fumeaux as CEO beginning February 2022. He started in April 2021 as the company’s Chief Medical Officer, and Co-CEO in September 2021
NETRIS Pharma selected by the European Innovation Council Accelerator among the most innovative startups and SMES companies in Europe
The selected companies will receive grants and/or equity investments, depending on their needs, up to a maximum of EUR 17.5 million.
Mablink Bioscience and Emergence Therapeutics Enter into a Licensing Agreement to Develop Antibody Drug Conjugate as a potential cancer therapy
Mablink Bioscience S.A.S. and Emergence Therapeutics AG today announced that they entered into a Licensing Agreement
ACTHERA Tx closes Seed A financing and strengthens team to advance its novel hard-shelled liposomes targeted release technology platform
Acthera Therapeutics AG, a biopharmaceutical company developing an innovative targeted release technology, announced today the completion of a CHF 5.4 million Seed A financing round
Mablink Bioscience, the next generation ADC company, raises €4 Million from a syndicate of private investors
Mablink Bioscience to move forward its ADC pipeline targeted at cancers with high unmet medical needs.
NETRIS Pharma Announces First Patient Dosed in Phase Ib/II
NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA®
NETRIS Pharma successfully completes a €16.1m Series A
NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer, today announced the closing of a €16.1m Series A financing and the reinforcement of its Board of Directors.